

# Anti-IL-23a Reference Antibody (risankizumab)

Recombinant Antibody

Catalog # APR10031

## Product Information

---

<b>Application</b>	FC, Kinetics, Animal Model
<b>Primary Accession</b>	<a href="#">Q9NPF7</a>
<b>Reactivity</b>	Human
<b>Clonality</b>	Monoclonal
<b>Isotype</b>	IgG1
<b>Calculated MW</b>	20730

## Additional Information

---

<b>Target/Specificity</b>	IL-23a
<b>Endotoxin</b>	
<b>Conjugation</b>	Unconjugated
<b>Expression system</b>	CHO Cell
<b>Format</b>	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

## Protein Information


---

<b>Name</b>	IL23A
<b>Synonyms</b>	SGRF
<b>Function</b>	Associates with IL12B to form the pro-inflammatory cytokine IL-23 that plays different roles in innate and adaptive immunity (PubMed: <a href="#">11114383</a> ). Released by antigen-presenting cells such as dendritic cells or macrophages, binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R to activate JAK2 and TYK2 which then phosphorylate the receptor to form a docking site leading to the phosphorylation of STAT3 and STAT4 (PubMed: <a href="#">29287995</a> , PubMed: <a href="#">32474165</a> , PubMed: <a href="#">33606986</a> ). This process leads to activation of several pathways including p38 MAPK or NF-kappa-B and promotes the production of pro-inflammatory cytokines such as interleukin-17A/IL17A (PubMed: <a href="#">12023369</a> ). In turn, participates in the early and effective intracellular bacterial clearance (PubMed: <a href="#">32474165</a> ). Promotes the expansion and survival of T-helper 17 cells, a CD4-positive helper T-cell subset that produces IL-17, as well as other IL-17-producing cells (PubMed: <a href="#">17676044</a> ).
<b>Cellular Location</b>	Secreted. Note=Secreted upon association with IL12B  Secreted by activated dendritic and phagocytic cells and keratinocytes. Also


Tissue Location

expressed by dermal Langerhans cells (at protein level).


Images



Anti-IL-23a Reference Antibody (risankizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-IL-23a Reference Antibody (risankizumab) is more than 100% ,determined by SEC-HPLC.



Immobilized human IL 23P40 His at 2 µg/mL can bind Anti-IL-23a Reference Antibody (risankizumab),EC50=0.04262 µg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.